Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Biotech Take Over - Wall Street Journal

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Dec 23, 2022 2:40pm

111 Views

Post# 35190141

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Biotech Take Over - Wall Street Journal

Yeah I thought about it TitanBrawler and I come up with the same hedge fund/MM pimp title for you. The kind that holds no shares in this stock but keeps "slapping" his wang to get his rocks off on this message board.

<< Previous

Bullboard Posts

Next >>

AI companies to invest in